SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-001582
Filing Date
2023-01-04
Accepted
2023-01-04 17:03:36
Documents
12
Period of Report
2023-01-04
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d441818d8k.htm   iXBRL 8-K 146337
  Complete submission text file 0001193125-23-001582.txt   285417

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ayla-20230104.xsd EX-101.SCH 2861
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ayla-20230104_lab.xml EX-101.LAB 18668
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ayla-20230104_pre.xml EX-101.PRE 11690
6 EXTRACTED XBRL INSTANCE DOCUMENT d441818d8k_htm.xml XML 3455
Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Filer) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39279 | Film No.: 23507661
SIC: 2836 Biological Products, (No Diagnostic Substances)